|
Genomic Expression named a finalist in XPrize Competition
 The XPrize incentivizes radical breakthroughs for humanity. Currently, it is holding a $5 million, 6-month competition to develop faster, cheaper, and better COVID-19 testing methods at scale. Genomic has applied its cancer treatment expertise in RNA sequencing to COVID-19
PCR testing requires significant processing and analytical time and costly reagents and most PCR machines can process only 100 tests per run. Genomic Expression has produced a verified workaround that only sequences some of the COVID RNA. This greatly cuts processing time and enables a machine to process thousands of test per day. Working with the XPrize,Genomic Expression has been able to test their processes at scale and to acquire large quantities of research-grade reagents, which are generally cost-prohibitive for small firms.
 Adeptrix has received a grant from the National Institute of Health (NIH) RADx program to develop and bring to the market a molecular diagnostic assay for SARS-CoV-2, which will be based on the company’s BAMS™ technology. As part of the award, Adeptrix has received access to various resources available through the RADx network to accelerate the FDA emergency use authorization of the BAMS™ SARS-CoV-2 assay.
The National Institutes of Health (NIH) launched the Rapid Acceleration of
Diagnostics (RADxSM) initiative to speed innovation in the development, commercialization, and implementation of technologies for COVID-19 testing. To learn more RADX, click here
|
Nth Cycle is NSIV's newest member. The company joined us in October. Moving its operations from Tennessee, Nth Cycle is represented here by 
MassBio 
